



Présentation / Intervention

2021

Open Access

This version of the publication is provided by the author(s) and made available in accordance with the copyright holder(s).

---

## Responsiveness of the S<sup>3</sup>-NIV questionnaire to severe episode of respiratory failure

---

Guerreiro, Ivan; Aline, Schmit; Schwarz, Esther Irene; Gasche-Soccal, Paola Marina Alessandra; Janssens, Jean-Paul; Adler, Dan Elie

### How to cite

GUERREIRO, Ivan et al. Responsiveness of the S<sup>3</sup>-NIV questionnaire to severe episode of respiratory failure. In: ERS International Congress 2021. Online. 2021. doi: 10.1183/13993003.congress-2021.PA3575

This publication URL: <https://archive-ouverte.unige.ch/unige:171975>

Publication DOI: [10.1183/13993003.congress-2021.PA3575](https://doi.org/10.1183/13993003.congress-2021.PA3575)

# Responsiveness of the S<sup>3</sup>-NIV questionnaire to severe episode of respiratory failure



Service de  
Pneumologie



Hôpitaux  
Universitaires  
Genève

I. Guerreiro<sup>1</sup>, A. Schmit<sup>1</sup>, E. Schwartz<sup>2</sup>, P.M. Soccà<sup>1,3</sup>, J.-P. Janssens<sup>1,3</sup>, D Adler<sup>1,3</sup>

<sup>1</sup>Division of Pulmonary Diseases, Geneva University Hospitals, Geneva <sup>2</sup> Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, <sup>3</sup> Geneva Medical School, Geneva, Switzerland

## Background

The S<sup>3</sup>-NIV questionnaire was recently developed to provide clinicians with a simple and reliable tool to assess important domains such as respiratory symptoms, sleep quality and NIV-related side-effects in patients treated with home NIV (figure 1).

Figure 1 : S<sup>3</sup>-NIV questionnaire score at day of admission and discharge for all items and two summary scales: Respiratory symptoms and Sleep-quality and NIV-related side-effects, respectively. The lowest possible score (0) corresponds to the highest impact of disease and treatment, while the highest possible score (10) corresponds to the lowest impact of disease and treatment.

## Aim

To test the responsiveness of the S<sup>3</sup>-NIV questionnaire to changes in health status during recovery from an acute episode of respiratory failure with hospital admission.

## Methods

The S<sup>3</sup>-NIV questionnaire was administered at hospital admission and hospital discharge in consecutive patients admitted for an acute episode of respiratory failure.

## Results

19 patients (8 males, median age 64yrs (interquartile range [IQR]: 55-76), treated with home NIV for a median time of 24 months (IQR: 14-51) were enrolled at admission. 10 patients were diagnosed with COPD, 4 with neuromuscular disorders, 2 with restrictive disorders, 2 patients with obesity hypoventilation syndrome, and 1 with central breathing disturbances during sleep. Median length of stay was 14 days (IQR: 7-22).

Figure 2: S<sup>3</sup>-NIV questionnaire score at day of admission and discharge. Each line represents an individual patient.

Mean S<sup>3</sup>-NIV questionnaire score at admission was 4.83 (SD 1.59, 95% CI 4.07 to 5.60) and 6.08 (SD 1.77, 95% CI 5.22 to 6.94) at discharge with a mean difference of 1.24 (SD 1.09, 95% CI 0.71 to 1.77, p<0.001) (figure 2).

Improvement of S<sup>3</sup>-NIV questionnaire score was more pronounced in COPD patients (1.39, 95%CI 0.58 to 2.19, p = 0.004), compared to non-COPD patients (1.08, 95%CI 0.24 to 1.92, p=0.02). Recovery from a severe exacerbation was associated with improvement in both the “respiratory symptoms” domain (1.61, 95%CI 0.78 to 2.43, p<0.001) and in the “sleep and NIV-related side-effects” domain (0.83, 95%CI 0.24 to 1.43, p=0.01)(figure 1).

## Conclusion

Our observation suggests that the S<sup>3</sup>-NIV questionnaire is responsive to recovery from severe respiratory exacerbation. Further studies to estimate MCID of the S<sup>3</sup>-NIV questionnaire using distribution and anchor-based methods are ongoing.

Dupuis-Lozeron E et al. Development and validation of a simple tool for the assessment of home noninvasive ventilation: the S<sup>3</sup>-NIV questionnaire. Eur Respir J 2018;52(5):1801182

